cytokines ͉ inflammasome ͉ Th1 ͉ Th17 ͉ Th2
Proinflammatory cytokines are often present at elevated levels in the course of inflammatory responses and infections. We queried whether these cytokines, particularly the prototypic proinflammatory cytokine IL-1␤ (2), might have a direct impact on CD4 T cell expansion.
IL-1 plays a significant role in immune responses to microorganisms as shown by greater and earlier morbidity and mortality to infections by various bacteria and viruses in the absence of IL-1R1 or MyD88 (3) (4) (5) . In humans, deficiency in IRAK-4, which is involved in IL-1 signal transduction (6) , leads to recurrent invasive bacterial infections (7) ; neutralization of IL-1 signaling by an IL-1 antagonist has caused septicemia in treated individuals (8) . IL-1 plays a major role in the induction of Th17 cells in humans (9). Th17 cells have been implicated in protective responses to extracellular bacteria (10, 11) , to Toxoplasma gondii (12) and to fungi (13) ; protective immunity in mice vaccinated with antigens from M. tuberculosis is mediated by IL-17 (14) . Humans with hyper IgE syndrome, who have defects in development of IL-17 producing cells, have recurrent infection with extracellular bacteria and fungi (15) .
Injection of IL-1␣ at the time of immunization has been reported to enhance primary responses, although to a relatively modest degree (16, 17) . In the latter study, the IL-1 effect was reported to be mediated through the action on antigen presenting cells (APCs) and its effect depended on the expression of CD28 on the part of the responding T cells, implying that it may have mimicked the action of TLR-engaging or inflammasomeactivating adjuvants on the ability of APC to mature. Indeed it had been shown that IL-1 plays a role in the regulation of DC activation (18, 19) , enabling the production of cytokines and enhancing the differentiation of naïve T cells (19, 20) .
We wished to determine whether continuous exposure to IL-1 and other proinflammatory cytokines might have a more robust effect than observed with single injections and might target the responding T cells as well as, or in preference to, DCs and/or other APCs, as might be anticipated from the role of IL-1 in promoting Th17 differentiation (9).
Results

IL-1 Enhances Primary and Secondary CD4 T Cell Responses.
Lymph node cells specific for a cytochrome C peptide/I-E k complex, from 5C.C7 Rag2 Ϫ/Ϫ CD45.1 donors, were injected into normal CD45.2 B10.A recipients. Recipients were immunized with pigeon cytochrome C (PCC) together with nothing, LPS or IL-1␤ (administered through a miniosmotic pump). On day 7, mice that received IL-1 had a Ͼ4-fold greater increase in the number of 5C.C7 cells among their peripheral blood mononuclear cells (PBMC) than mice that received LPS (Fig. 1A) . When footpad immunization was used, the IL-1 group had a 12-fold greater response than the LPS group. Comparable results were obtained by analysis of lymph nodes and spleens from immunized mice (Fig. S1 A) .
Among a series of proinflammatory cytokines tested, including TNF␣, IL-6, IL-18 and IL-33, only IL-1 increased the degree of expansion of 5C.C7 cells in response to PCC immunization ( Fig. 1B and data not shown) . IL-1␣ and IL-1␤ displayed similar potency (Fig. S1B) .
Priming in the presence of IL-1␤ gave rise to greater persistence of memory cells than did priming in the presence of LPS. Mice that had received 5C.C7 cells were primed with PCC in a miniosmotic pump. Some animals additionally received LPS or IL-1. Sixteen months later, the mice that had received IL-1 had 54,000 5C.C7 in their lymph nodes and 77,000 in their spleens whereas those that had received LPS had barely detectable numbers of 5C.C7 cells and those that had not, undetectable numbers ( Fig. 2A) .
The response of memory cells was also enhanced by IL-1. Mice received 5C.C7 cells and were primed with PCC administered s.c. with LPS. Seven months later they were challenged with PCC with or without the addition of exogenous cytokines.
IL-1␤ caused a 26-fold greater expansion of memory cells compared with the expansion caused by antigen alone. No significant increase in antigen-mediated expansion of primed cells was caused by IL-2, IL-4, IL-7, IL-9, IL-15, IL-21 or TNF␣ (Fig. 2B ).
antigen caused a 3-fold greater increase in the frequency of 5C.C7 cells than occurred in comparable mice that had not received IL-1 (Fig. 3A) .
When CD28 Ϫ/Ϫ 5C.C7 cells were stimulated in intact B10.A recipients, IL-1 markedly enhanced their response to PCC, indicating that CD28 expression on responding T cells is not essential for the IL-1 effect (Fig. 3B) .
IL-1 Enhancement Is Seen in
Responses by Polyclonal Cells. C57BL/6 mice were immunized using a miniosmotic pump with or without IL-1 with a peptide representing positions 61 to 80 of the lymphocytic choriomeningitis virus (LCMV) glycoprotein, the dominant CD4 epitope (21) . Seven days later, among CD44 bright , V␣2 ϩ CD4 lymph node T cells from mice immunized with peptide and IL-1, 6.6% of the cells bound a tetramer composed of the gp 66-77 peptide bound to the I-A b class II MHC molecule, compared with 2.9% of comparable cells from mice immunized with peptide without IL-1 (Fig. 4A) .
We also tested the effect of IL-1 on production of antiovalbumin (OVA) antibody 14 days after immunization of B6 mice with OVA with or without IL-1. Immunization with OVA in a miniosmotic pump caused only a modest increase in serum antibody titer over that seen in unimmunized mice. By contrast, mice that also received IL-1 showed a striking increase in their ELISA titer of the T cell-dependent IgG1 anti-OVA antibody (Fig. 4B ) further indicating that IL-1 enhanced normal CD4 T cell mediated immune responses.
Increased Cell Proliferation Cannot Completely Account for the IL-1
Effect. The 5C.C7 cells were labeled with 5,6-carboxy-succinimidylfluoresceine-ester (CFSE) and transferred to B10.A recipients that were immunized with PCC in a miniosmotic pump with or without IL-1. On days 2, 3 and 4, cells from mice that had received IL-1 showed an increased number of cell divisions ranging from 0.6 to 1.1 (Table S1 ). Although the increased cell division on day 2 could account for most of the increase in cell number mediated by IL-1 at that time, it could only account for a small portion of the increased expansion in cell number seen on days 3 and 4. On those days, IL-1 caused an Ϸ9-fold (day 3) or 7-to 8-fold (day 4) greater expansion. Thus, increased survival is the dominant factor in the IL-1-mediated enhancement of expansion at later times. When WT and IL-1R1 Ϫ/Ϫ OT-II cells were cotransferred to Rag 1 Ϫ/Ϫ IL-1R1 Ϫ/Ϫ recipients, IL-1 stimulated a marked increase in the antigen-driven response of the WT OT-II cells but had essentially no effect on the KO OT-II cells (Fig. 5B) . Thus, cells responding to IL-1 did not enhance the response of cells of the same specificity that were themselves incapable of responding to IL-1.
When IL-1R1
Ϫ/Ϫ OT-II cells were stimulated in WT B6 recipients in the presence of IL-1 plus LPS, the KO T cells showed a relatively modest IL-1-mediated increase in cell expansion compared with similarly treated WT OT-II cells in WT recipients (Fig. 5D ), implying that the major effect of IL-1 was on the responding CD4 T cells.
IL-1 Enhances Priming for IL-17 and IL-4 Production by WT T cells
Immunized in IL-1R1 ؊/؊ Recipients. IL-1 strikingly increased the frequency of IL-17-producing cells, in response to OVA, in both lymph node and spleen among OT-II cells transferred to IL-1R1 Ϫ/Ϫ or WT recipients. IL-1 also increased the frequency of IL-4-producers but only in IL-1R1 Ϫ/Ϫ recipients. The frequency of IFN␥ producers was increased as well although more modestly than IL-4-or IL-17-producers (Fig. 6A) . A similar analysis was done in the Rag1 Ϫ/Ϫ IL-1R1 Ϫ/Ϫ recipients of OT-II cells. The results were even more dramatic with the IL-1-induced frequency of IL-17 producers in lymph node being Ϸ20% and of IL-4-producers Ͼ40%. In the spleen, IL-17 producers were Ͼ40% in the presence of IL-1.
In IL-1R1 Ϫ/Ϫ recipients of WT OT-II cells immunized with OVA plus LPS, IL-1 caused a Ͼ64-fold increase in serum IgE concentration, to 6.6 g/mL (Fig. 6B) , and a 6-fold increase in serum IgG1 concentration.
IL-1 Enhances Antigen-Stimulated Proliferation of Th1, Th2 and Th17
Cells. OT-II cells were primed in vitro under Th1, Th2 and Th17 polarizing conditions and 0.8 (Th17) to 2 ϫ 10 6 (Th1 and Th2) cells transferred to 1L-1R1 Ϫ/Ϫ Rag1 Ϫ/Ϫ recipients. The mice were then challenged with OVA administered in a miniosmotic pump with or without IL-1.
IL-1 resulted in a markedly greater expansion of the Th2 and Th17 cells. IL-1 also caused an enhanced expansion of Th1 cells ( Fig. 7) , although the degree of enhancement was less striking than that of the Th2 and Th17 cells. That the cells that did expand under the influence of IL-1 were actually Th1 cells was shown by the finding that 40% or more of these cells produced IFN␥ upon stimulation. Thus, IL-1 not only could enhance priming of each cell type but could also enhance response of already differentiated cells.
IL-1 Accounts for a Portion of the LPS Effect on 5C.C7 Cell Expansion.
B10.A recipients of 5C.C7 cells were challenged with PCC in a miniosmotic pump or s.c. with LPS in the presence or absence of the IL-1 receptor antagonist (IL-1Ra). In a series of 4 experiments, 5C.C7 cell expansion was diminished to 44% of control by IL-1Ra (95% confidence interval of the estimate was 8% to 70%) ( Table  1 ), indicating that IL-1 is responsible for a large portion of the adjuvant effects of LPS and miniosmotic pumps. The effect of exogenous IL-1 in increasing CD4 T cell responses to antigenic challenge is particularly notable in view of recent work indicating that alum mediates much of its adjuvant activity through activation of the NLRP3/NALP3 inflammasome with consequent production of IL-1, IL-18 and possibly IL-33 (22) . Indeed, antigen-specific antibody responses to immunization with alum as an adjuvant were significantly impaired in mice deficient in NALP3/NLRP3 (22) .
In our experiments, the responding T cell was the major target of IL-1 and its response was cell autonomous, in contrast to the report by Khoruts et al. (17) . Indeed, CD28
Ϫ/Ϫ OT-II cells showed a robust increase in response to IL-1 plus antigen over that to antigen alone.
IL-1 has been shown to promote the differentiation of naïve CD4 T cells into Th17 cells (9) and to promote expansion of IL-17-secreting memory CD4
ϩ T cells (23) . Functional IL-1Rs have been detected on mature Th17 and Th2 cells (24, 25) although their expression on Th1 clones has not been shown (25) . It is striking that IL-4 and IL-17 were produced by a significant proportion of WT OT-II cells primed, in the presence of IL-1, in IL-1R1 Ϫ/Ϫ recipients. This result is also in keeping with the known effects of alum in promoting IgE and IgG1 responses (26) and in the very striking increases in IgE and IgG1 we observed 7 days after priming when IL-1 was used in immunizing IL-1R1 Ϫ/Ϫ recipients of WT OT-II cells. This is also consistent with the striking inhibition of these 2 IL-4-dependent Ig classes when antigen is administered in alum to inflammasome-deficient mice (22) and with the important role of IL-1 in regulating Th2 responses during gastrointestinal nematode infection (27) . However, IL-1 not only caused a Ͼ30-fold increase in expansion of primed Th17 OT-II cells transferred to B6 1L-1R1 Ϫ/Ϫ Rag1 Ϫ/Ϫ recipients upon challenge with OVA and IL-1 and a Ͼ10-fold increase in Th2 cells, it also caused a 4-7-fold increase in the expansion of Th1 cells. This is striking in so far as IL-1 receptors have not been detected on Th1 cells (25) Although IL-1 induces IL-6 (29) and IL-6 augments the replication and survival of stimulated CD4 T cells both in vitro and in vivo (30) , the effect of IL-1 on stimulated CD4 cells does not require IL-6 activity. In a system in which the 5C.C7 donor T cells and the recipients were both IL-6-deficient, an IL-1 effect was obtained.
We failed to detect Foxp3ϩ cells among naïve OT-II or OT-II IL-1R1 Ϫ/Ϫ cells and the frequency of such cells 2 days after in vivo challenge of OT-II cells, Ϸ2%, makes it unlikely that IL-1 mediates its function by blocking Tregs.
CFSE analysis indicates that IL-1-mediated increased replication can only account for an Ϸ2-fold increase in expansion whereas the actual increase in cell expansion was 7-to 8-fold, implying that much of the IL-1 effect must be due to enhanced survival. The precise mechanism by which IL-1 enhances the survival and the proliferation of the stimulated cells is still unknown but activation of MyD88 and of the NF-B pathway, both of which are engaged by IL-1, promotes proliferation and survival of activated CD4 T cells (31, 32) .
IL-1Ra partially inhibited the response of T cells to antigen plus LPS or to antigen delivered by a miniosmotic pump. The failure to obtain complete inhibition may be due to the degree of activity of IL-1Ra and/or its short half life in vivo, but prior reports indicating only partial diminution of immune responses in IL-1 KO mice (5, 33) and upon administration of IL-1Ra into mice with autoimmune diseases (34, 35) imply that IL-1 may play a redundant role in this process. Indeed, NALP3-/NLRP3-deficient mice showed good responses to complete Freund's adjuvant although the adjuvant action of alum was inhibited (22) confirming an earlier observation that anti-IL-1 antibodies inhibited a T cell proliferative response after immunization with an alum adjuvant but not with Freund's complete adjuvant (36) .
IL-1's striking proinflammatory effects would seem to preclude its use in most preventive vaccines, particularly in healthy individuals. However, in therapeutic vaccines for tumors or chronic infections, ''side effects'' might be more easily accepted, suggesting that IL-1 might be used as an adjuvant under controlled conditions. Understanding the molecular basis of IL-1's activity in CD4 T cells will be essential if we are to use T cell-specific members of this pathway as targets of novel adjuvants of limited toxicity or for drugs aimed at suppressing pathological CD4 T cell responses.
Materials and Methods
Mice. Female mice of the strains specified in SI Materials and Methods were obtained from Taconic Farms and from the Jackson laboratory. Mice were maintained under pathogen-free conditions and were used at 6 -8 weeks of age. IL-1 receptor antagonist (IL-1Ra) (25 g) SC with or without IL-1Ra that was given daily by IP injections for 6 -7 days (1.25 mg per injection) or mini-osmotic pumps containing 1 mg PCC with or without IL-1Ra (200 g) were implanted. Six to 13 days after immunization, the percentage of 5C.C7 cells among the PBMCs or in the lymphoid organs was determined as described in Materials and Methods. The fractional response in the presence of IL-1Ra is shown.
Cytokines and Abs. Recombinant cytokines (as specified in SI Materials and Methods) were purchased from PeproTech and R&D Systems. The gp 61-80 peptide was purchased from American Peptide. Fluorochrome-conjugated Abs (as specified in SI Materials and Methods), were purchased from BD PharMingen. and eBioscience. APC-IA b restricted gp 66 -77 tetramer was obtained from the National Institutes of Health Tetramer Core Facility. IL-1Ra (Anakinra) was obtained from the University of Colorado Hospital Pharmacy (Denver, CO).
Generation of Th1, Th2 and Th17 In Vitro. Lymph node cells from OT-II/RAG-1 Ϫ/Ϫ B6 mice were primed in vitro with irradiated (30 Gy) T-depleted B6 splenocytes and OVA peptide 323-339 under Th1, Th2 or Th17 as specified in the SI Materials and Methods. After 4 days, the cells were washed and rested for a week in IL-2 (100 units/mL) (Th1 and Th2) or in IL-23 (20 ng/mL) (Th17). A second round of identical stimulation and rest period were performed.
Tetramer Staining. Lymph node or spleen cells (2 ϫ 10 6 ) were incubated for 30 min. at 37C in 0.2 mL of culture medium with APC conjugated IA b -restricted gp66 -77 tetramer (2 g/mL) followed by staining at 4C for 30 min. with FITC anti-CD44, PE anti-V␣2 and PE Cy7 anti-CD4. Cells were washed in PBS with 0.1%BSA and analyzed with a BD LSRII, using FlowJo software (Tree Star).
Intracellular Cytokine Staining. Spleen and lymph node cells were stimulated with ionomycin and phorbol 12-myristate 13-acetate (PMA), fixed, permeabilized and stained as specified in SI Materials and Methods. The stained cells were analyzed with a BD LSRII, using FlowJo software (Tree Star, Inc).
In Vivo Priming of Adoptively Transferred Transgenic Cells. Unless otherwise specified, cells (0.5 to 2 ϫ 10 6 ) from lymph nodes of transgenic donor mice were injected i.p. (IP) into normal syngeneic B10.A or C57BL/6 mice (3-5 mice for each experimental group). In the experiments, the OT-II lymph node cells were enriched for CD4 cells by passage over T enrichment column (R&D Systems) before transfer to the recipient C57BL/6 mice. In some experiments, mice were immunized 7-10 days later by implantation of miniosmotic pumps (Durect) containing 10 -1,000 g of antigen (PCC or OVA) (Sigma-Aldrich) with or without cytokine (10 g) in HBSS for 7 days. In other experiments, mice were immunized s.c. or in the foot pads (FP) by injection of 500-1000 g of antigen (PCC or OVA) with or without 25 g of LPS (Escherichia coli 0111:B4; InvivoGen). Some of the s.c.-or FP-immunized mice were given IL-1␤ (10 g) that was delivered for 7 days by miniosmotic pumps that were implanted in the mice at the day of immunization.
Monitoring Donor CD4 Transgenic Cells. At specified times, the percentage of 5C.C7 donor cells among the PBMCs in the blood or in the single cell suspensions of the lymphoid organs was determined by staining with FITC-anti-CD45.1, PE-anti-V␤3, APC-anti-CD45.2 and PE Cy7-anti-CD4 Abs in the presence of anti-Fc␥RII/III Abs (2.4G2) followed by flow cytometric analysis with a FACSCalibur and CellQuest software and identification of the CD4 ϩ /V␤3 ϩ /CD45.1 ϩ /CD45.2 Ϫ cells.
The percentage of the OT-II donor cells in the blood samples and the lymphoid organs of the recipient mice was determined by staining with FITC-anti-V␤5, PE-anti-V␣2 and APC-anti-CD4 Abs and the identification of the CD4 ϩ /V␣2 ϩϩ /V␤5 ϩ Tg cells. The number of 5C.C7 or OT-II cells in the lymphoid organs was determined by multiplying the cell number in the organ by the fraction of Tg cells in that organ.
Cell Division Analysis. Lymph node cells from 5C.C7/RAG-2 Ϫ/Ϫ /CD45.1 mice were labeled with CFSE as described in ref. 30 . The CFSE labeled cells were injected IP into syngeneic B10.A mice. After 7 days, the recipient mice were implanted with miniosmotic pumps containing PCC (1 mg) with or without IL-1␤ (10 g). Two, 3, or 4 days later, lymph nodes and spleens were removed, stained with PE-anti-V␤3, APC-anti-CD45.1 and PE Cy7-anti-CD4. The percentage of cells in various CFSE peaks among CD4 ϩ /V␤3 ϩ /CD45.1 ϩ population was determined by analysis with a FACSCalibur and CellQuest software.
Measurement of Serum OVA-Specific IgG1 Antibodies. The relative concentration of IgG1 anti-OVA in the sera was determined by sandwich Elisa on OVA coated Immulon plates (Thermo Scientific) with HRP-conjugated goat antimouse IgG1 Abs (Southern Biotechnology). 10 3 ) were transferred into CD45.2 B10.A mice. Seven days later, mice were immunized by SC injection of 1 mg PCC with or without 25 g LPS. rIL-1␤ (10 g) in a miniosmotic pump was administered for 7 days to the mice that were immunized with PCC without LPS. Seven days later, the percentage of CD4 ϩ /V␤3 ϩ /CD45.1 ϩ /CD45.2 Ϫ cells in the lymph nodes (LN) and spleens (SP) was determined as described in Materials and Methods. (B). IL-1␣ and IL-1␤ have similar potency as enhancers of the primary immune response. 5C.C7/RAG-2 Ϫ/Ϫ /CD45.1 B10.A lymph node (0.7 ϫ 10 6 ) and spleen (2 ϫ 10 6 ) cells were transferred IP into normal CD45.2 B10.A mice. Eight days later, mice were immunized by implantation of miniosmotic pumps containing 1 mg PCC with either rIL-1␣ (10 g), or rIL-1␤ (10 g). Seven days later, blood cells of the immunized mice were stained for CD4, V␤3, CD45.1 and CD45.2 as described in Materials and Methods and the percentage of CD4 ϩ /V␤3 ϩ /CD45.1 ϩ /CD45.2 Ϫ cells among the white blood cells was determined. Fig. S2 . IL-1 administration achieves higher serum IL-1 concentrations in IL-1R1 Ϫ/Ϫ recipients than in normal mice. Mice from the experiment described in the Legend to Fig. 5A were bled 7 days after implantation of miniosmotic pumps and serum concentration of IL-1␤ determined with the multiplex system from MesoScaleDiscovery. Table S1 . Increased cell expansion in IL-1-treated mice is more than can be accounted for by enhanced cell replication CFSE-labeled 5C.C7/RAG-2 Ϫ/Ϫ /CD45.2 B10.A lymph node cells (2 ϫ 10 6 ) were transferred into CD45.1 B10.A mice. Seven days later, mini-osmotic pumps containing PCC (1 mg) with or without rIL-1␤ (10 g) were implanted. Two, 3, and 4 days after priming, the number of CD4 ϩ /V␤3ϩ/CD45.2 ϩ T cells in lymph nodes and spleens was determined by FACS analysis as specified in Materials and Methods and the IL-1-induced increase in the number of the 5C.C7 cells was calculated. The CFSE-labeled CD4 ϩ /V␤3ϩ/CD45.2 ϩ cells were analyzed for their degree of replication by CFSE dilution, and the mean number of cell divisions was calculated.
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